Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COYA Coya Therapeutics	$5.41 +1.5%	$5.87	$4.65 ▼ $10.24	$90.48M	0.49	72,400 shs	45,700 shs
GBIO Generation Bio	$0.37 -4.1%	$0.39	$0.32 ▼ $3.65	$25.08M	2.76	309,261 shs	294,477 shs
KYTX Kyverna Therapeutics	$2.52 -4.2%	$2.14	$1.78 ▼ $16.64	$108.91M	2.17	419,119 shs	187,872 shs
MDCX Medicus Pharma	$2.45 -32.5%	$4.51	$1.80 ▼ $8.94	$33.06M	N/A	115,339 shs	1.97 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COYA Coya Therapeutics	0.00%	-8.31%	-15.07%	-26.89%	-29.00%
GBIO Generation Bio	0.00%	+1.08%	-14.18%	-30.35%	-88.24%
KYTX Kyverna Therapeutics	0.00%	+11.01%	+10.53%	-2.70%	-79.89%
MDCX Medicus Pharma	0.00%	-66.39%	-44.44%	-35.53%	+244,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COYA Coya Therapeutics	1.8249 of 5 stars	3.5	3.0	2.0	0.8	0.0
GBIO Generation Bio	3.3041 of 5 stars	3.5	3.0	2.3	3.3	1.3
KYTX Kyverna Therapeutics	1.7355 of 5 stars	3.6	1.0	2.6	1.7	0.0
MDCX Medicus Pharma	1.7542 of 5 stars	3.8	0.0	2.4	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COYA Coya Therapeutics	3.00	Buy	$17.00	214.23% Upside
GBIO Generation Bio	3.00	Buy	$7.33	1,860.26% Upside
KYTX Kyverna Therapeutics	3.14	Buy	$18.50	634.13% Upside
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	859.18% Upside

Current Analyst Ratings Breakdown

Latest GBIO, COYA, MDCX, and KYTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/27/2025	KYTX Kyverna Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $5.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/22/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00 ➝ $18.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COYA Coya Therapeutics	$3.69M	24.55	N/A	N/A	$2.47 per share	2.19
GBIO Generation Bio	$24.56M	1.02	N/A	N/A	$3.07 per share	0.12
KYTX Kyverna Therapeutics	$7.03M	15.49	N/A	N/A	N/A	∞
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COYA Coya Therapeutics	-$7.99M	-$1.07	N/A	N/A	N/A	N/A	-31.63%	-27.76%	8/11/2025 (Estimated)
GBIO Generation Bio	-$126.61M	-$1.08	N/A	N/A	N/A	-782.86%	-104.85%	-49.54%	8/6/2025 (Estimated)
KYTX Kyverna Therapeutics	-$60.37M	-$3.38	N/A	N/A	N/A	N/A	-51.12%	-37.91%	8/11/2025 (Estimated)
MDCX Medicus Pharma	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	6/27/2025 (Estimated)

Latest GBIO, COYA, MDCX, and KYTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	COYA Coya Therapeutics	-$0.44	-$0.44	N/A	-$0.44	$2.63 million	$257.88 million
5/13/2025	Q1 2025	KYTX Kyverna Therapeutics	-$1.21	-$1.03	+$0.18	-$1.03	N/A	N/A
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A
3/27/2025	Q4 2024	KYTX Kyverna Therapeutics	-$0.87	-$0.88	-$0.01	-$0.88	N/A	N/A
3/19/2025	Q4 2024	GBIO Generation Bio	-$0.31	-$0.32	-$0.01	-$0.32	$2.92 million	$4.19 million
3/18/2025	Q4 2024	COYA Coya Therapeutics	-$0.32	-$0.18	+$0.14	-$0.18	$0.10 million	$0.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
KYTX Kyverna Therapeutics	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COYA Coya Therapeutics	N/A	15.31	15.31
GBIO Generation Bio	N/A	6.34	6.34
KYTX Kyverna Therapeutics	N/A	10.50	10.50
MDCX Medicus Pharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COYA Coya Therapeutics	39.75%
GBIO Generation Bio	95.22%
KYTX Kyverna Therapeutics	18.08%
MDCX Medicus Pharma	N/A

Insider Ownership

Company	Insider Ownership
COYA Coya Therapeutics	12.00%
GBIO Generation Bio	21.80%
KYTX Kyverna Therapeutics	22.00%
MDCX Medicus Pharma	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COYA Coya Therapeutics	6	16.73 million	14.70 million	Not Optionable
GBIO Generation Bio	150	67.04 million	52.70 million	Optionable
KYTX Kyverna Therapeutics	96	43.22 million	N/A	Optionable
MDCX Medicus Pharma	N/A	13.50 million	N/A	N/A

GBIO, COYA, MDCX, and KYTX Headlines

Recent News About These Companies

Medicus Pharma (NASDAQ:MDCX) Upgraded to "Hold" at Wall Street Zen

May 31 at 2:49 AM | americanbankingnews.com

Medicus Pharma (NASDAQ:MDCX) Upgraded at Wall Street Zen

May 31 at 2:08 AM | marketbeat.com

Medicus Pharma (NASDAQ:MDCX) Earns Buy Rating from D. Boral Capital

May 31 at 1:23 AM | americanbankingnews.com

D. Boral Capital Reiterates "Buy" Rating for Medicus Pharma (NASDAQ:MDCX)

May 30 at 9:00 AM | marketbeat.com

Medicus Pharma unveils pricing of $7M public offering

May 30 at 8:36 AM | proactiveinvestors.com

Medicus Pharma prices $7 million share offering

May 30 at 5:31 AM | msn.com

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering | MDCX Stock News

May 29, 2025 | gurufocus.com

Medicus Pharma Ltd. Launches $7 Million Public Offering to Advance Cancer Treatment Trials

May 29, 2025 | tipranks.com

Medicus Pharma Ltd. Announces Pricing of $7.0 Million Public Offering

May 29, 2025 | newsfilecorp.com

MDCX Medicus Pharma Ltd.

May 29, 2025 | seekingalpha.com

Medicus Pharma begins UAE cancer trial expansion â€“ ICYMI

May 25, 2025 | proactiveinvestors.com

Medicus Pharma begins UAE cancer trial expansion – ICYMI

May 25, 2025 | proactiveinvestors.com

Medicus Pharma's (MDCX) Buy Rating Reaffirmed at D. Boral Capital

May 24, 2025 | marketbeat.com

Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy

May 22, 2025 | proactiveinvestors.com

Medicus Pharma gets UAE approval for Phase 2 study for skin cancer therapy

May 22, 2025 | proactiveinvestors.com

Medicus Pharma Ltd Receives Study May Proceed Approval from United Arab Emirates (UAE) Department of Health (DOH) to Commence Phase 2 Clinical Study (SKNJCT-004) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

May 22, 2025 | newsfilecorp.com

Medicus Pharma Ltd. (NASDAQ:MDCX) Major Shareholder Velocity Fund Partners, Lp Sells 75,000 Shares

May 22, 2025 | insidertrades.com

Medicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Misses Estimates By $0.19 EPS

May 14, 2025 | marketbeat.com

D. Boral Capital Boosts Medicus Pharma (NASDAQ:MDCX) Price Target to $27.00

May 14, 2025 | marketbeat.com

Medicus Pharma Ltd

May 14, 2025 | cnn.com

Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio

May 12, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GBIO, COYA, MDCX, and KYTX Company Descriptions

Coya Therapeutics NASDAQ:COYA

$5.41 +0.08 (+1.50%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.33 -0.08 (-1.48%)

As of 07:48 AM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Generation Bio NASDAQ:GBIO

$0.37 -0.02 (-4.08%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.39 +0.01 (+3.45%)

As of 08:34 AM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Kyverna Therapeutics NASDAQ:KYTX

$2.52 -0.11 (-4.18%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.66 +0.15 (+5.75%)

As of 08:09 AM Eastern

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Medicus Pharma NASDAQ:MDCX

$2.45 -1.18 (-32.51%)

As of 05/30/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time